PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33629198-8 2021 Moreover, in vitro, c-Met inhibitors Foretinib, Crizotinib and Cabozantinib were significantly more effective against TEC-Dys than TEC-Ortho. Crizotinib 48-58 met proto-oncogene Mus musculus 20-25 33676682-5 2021 Herein, we developed a new small molecular fluorescence probe, namely Crizotinib-PEG4-MPA, specifically binds to c-Met in CRC cells and colitis-associated cancer adenoma. Crizotinib 70-80 met proto-oncogene Mus musculus 113-118 33676682-6 2021 In vitro binding studies confirmed the specificity and selectively of Crizotinib-PEG4-MPA against c-Met, the corresponding apparent equilibrium dissociation constants (Kd) was 3.86 muM for Crizotinib-PEG4-MPA. Crizotinib 70-80 met proto-oncogene Mus musculus 98-103 33676682-6 2021 In vitro binding studies confirmed the specificity and selectively of Crizotinib-PEG4-MPA against c-Met, the corresponding apparent equilibrium dissociation constants (Kd) was 3.86 muM for Crizotinib-PEG4-MPA. Crizotinib 189-199 met proto-oncogene Mus musculus 98-103 22269210-5 2012 Interestingly, Crizotinib (a dual inhibitor of c-Met and ALK pathways) as single agent or in combination with sunitinib reduced metastasis in all models tested suggesting a role for c-Met/HGF pathway in intrinsic- or sunitinib-induced-metastasis. Crizotinib 15-25 met proto-oncogene Mus musculus 47-52 26531163-4 2015 The selective c-MET inhibitor, PF-2341066, can induce PEL apoptosis through cell cycle arrest and DNA damage, and suppress tumor progression in a xenograft murine model. Crizotinib 31-41 met proto-oncogene Mus musculus 14-19 24220141-10 2013 The c-Met inhibitor crizotinib reduced MACC1-induced migration and tumor formation in organotypic hippocampal slice cultures of mice. Crizotinib 20-30 met proto-oncogene Mus musculus 4-9 22233293-1 2012 BACKGROUND AND PURPOSE: Besides targeting the well-known oncogenic c-Met, crizotinib is the first oral tyrosine kinase inhibitor inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non-small cell lung cancer. Crizotinib 74-84 met proto-oncogene Mus musculus 67-72 22233293-4 2012 To understand the mechanisms for MDR reversal, the alterations of intracellular doxorubicin or rhodamine 123 accumulation, doxorubicin efflux, ABCB1 expression level, ATPase activity of ABCB1 and crizotinib-induced c-Met, Akt and ERK1/2 phosphorylation were examined. Crizotinib 196-206 met proto-oncogene Mus musculus 215-220 32827692-6 2020 These beneficial effects of HGF were blocked by HGF/c-Met inhibitor Crizotinib or phosphatidylinositide 3-kinases (PI3K) inhibitor LY294002. Crizotinib 68-78 met proto-oncogene Mus musculus 52-57 29440379-7 2018 Using this model, we discovered that cMET blockade by crizotinib (CRZ) enhanced schwannoma radiosensitivity by enhancing DNA damage, and CRZ treatment combined with low-dose radiation was as effective as high-dose radiation. Crizotinib 54-64 met proto-oncogene Mus musculus 37-41 29440379-7 2018 Using this model, we discovered that cMET blockade by crizotinib (CRZ) enhanced schwannoma radiosensitivity by enhancing DNA damage, and CRZ treatment combined with low-dose radiation was as effective as high-dose radiation. Crizotinib 66-69 met proto-oncogene Mus musculus 37-41 29440379-9 2018 This cMET gene knockdown study independently confirmed the role of the cMET pathway in mediating the effect of CRZ. Crizotinib 111-114 met proto-oncogene Mus musculus 5-9 29440379-9 2018 This cMET gene knockdown study independently confirmed the role of the cMET pathway in mediating the effect of CRZ. Crizotinib 111-114 met proto-oncogene Mus musculus 71-75 27057482-0 2016 cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer. Crizotinib 15-25 met proto-oncogene Mus musculus 0-4 27057482-9 2016 In sum, cMET inhibition by crizotinib limited tumor development and microvascular density in basal-like tumor-bearing mice but did not appear to be an effective preventive agent for BBC. Crizotinib 27-37 met proto-oncogene Mus musculus 8-12 25193856-1 2014 Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. Crizotinib 0-10 met proto-oncogene Mus musculus 14-19 25277255-4 2014 In this study we tested multi-kinase inhibitors: axitinib (VEGFR inhibitor) and crizotinib (c-MET inhibitor) in a combination trial in mice models. Crizotinib 80-90 met proto-oncogene Mus musculus 92-97 24170771-3 2014 Fifty percent of the thyroid cancer cell lines (four of eight) were growth inhibited by two small molecule c-MET inhibitors (tivantinib and crizotinib) associated with apoptosis and G(2)-M cell-cycle arrest. Crizotinib 140-150 met proto-oncogene Mus musculus 107-112 24170771-9 2014 In summary, c-MET inhibitors (tivantinib and crizotinib) suppress the growth of aggressive thyroid cancer cells, and this potential therapeutic benefit results from their non-MET-targeting effects. Crizotinib 45-55 met proto-oncogene Mus musculus 12-17 24140933-0 2013 Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Crizotinib 0-10 met proto-oncogene Mus musculus 14-19 24140933-2 2013 Crizotinib, an inhibitor of c-Met, anaplastic lymphoma kinase (ALK), and ROS1, inhibited the phosphorylation of the c-Met receptor but not of ALK or ROS1 in uveal melanoma cells and tumor tissue. Crizotinib 0-10 met proto-oncogene Mus musculus 28-33 22269210-5 2012 Interestingly, Crizotinib (a dual inhibitor of c-Met and ALK pathways) as single agent or in combination with sunitinib reduced metastasis in all models tested suggesting a role for c-Met/HGF pathway in intrinsic- or sunitinib-induced-metastasis. Crizotinib 15-25 met proto-oncogene Mus musculus 182-187 22585997-4 2012 However, invasion and metastasis were reduced by concurrent inhibition of c-Met by PF-04217903 or PF-02341066 (crizotinib). Crizotinib 111-121 met proto-oncogene Mus musculus 74-79